Spots Global Cancer Trial Database for Adbelizumab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Adbelizumab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
Official Title: A Single-arm, Single-center, Exploratory Study of Adbelizumab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
Study ID: NCT06177522
Study Description
Brief Summary: Clinical Study on the Safety and Efficacy of the efficacy and safety of adbelizumab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer
Detailed Description: The goal of this clinical trial is to observe and evaluate the efficacy and safety of adbelizumab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer.The main questions it aims to answer are: To investigate the feasibility of immunotherapy combined with chemotherapy in the neoadjuvant therapy of pancreatic cancer. To explore more effective neoadjuvant therapies for pancreatic cancer. Participants will receive 2 cycles of aldebelizumab in combination with albumin-bound paclitaxel and gemcitabine in the neoadjuvant phase, followed by surgery.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Wang Sizhen, Nanjing, Jiangsu, China
Contact Details
Name: Xinbo Wang, MD
Affiliation: Jinling Hospital, China
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
